TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION AND ITS PRODROMALSTAGE WITH GABAXATE MESILATE (FOY) - A MULTICENTER TRIAL

One hundred and ninety-one patients with disseminated intravascular co agulation syndrome (DIC) or its prodromal stage (preDIC) were treated with only gabaxate mesilate (FOY(R)) (group G) or a combination of gab axate and unfractionated heparin (group GH), and the efficacy of gabax ate was evaluated in a multicenter study. Following the treatment, the mean DIC score, which was evaluated on the basis of clinical symptoms and hemostatic parameters, decreased significantly to 5.58 +/- 3.48 f rom 6.75 +/- 3.14 in group G (p < 0.001) and to 6.34 +/- 3.33 from 7.3 1 +/- 3.00 in group GH (p < 0.05). In patients with overt DIC, the mea n score decreased to 6.71 +/- 3.54 from 8.42 +/- 2.84 (p < 0.001). In DIC, the rate of overall efficacy was 46.2% in group G and 35.1% in gr oup GH. In preDIC, it was 41.5% in group G and 27.3% in group GH. No s ide effects, including severe bleeding, were found in this study. The results indicate that gabaxate mesilate is clinically effective for pa tients with DIC and preDIC.